Wellington Management Group LLP and three affiliated entities filed an amended beneficial ownership statement with the SEC on November 16, 2026, disclosing a combined stake of 4,681,855 shares of Stoke Therapeutics, Inc. common stock as of September 30, 2026.

Key Highlights

  • Aggregate beneficial ownership: Wellington Management Group LLP reported 4,681,855 shares of Stoke Therapeutics common stock, representing 7.3% of the class.
  • Shared voting power: Wellington Management Group LLP, Wellington Group Holdings LLP, and Wellington Investment Advisors Holdings LLP each reported shared voting power over 4,417,811 shares, with zero sole voting power.
  • Shared dispositive power: Wellington Management Group LLP, Wellington Group Holdings LLP, and Wellington Investment Advisors Holdings LLP each reported shared dispositive power over 4,681,855 shares.
  • Wellington Management Company LLP: As the operating investment adviser, it reported shared voting power over 4,417,106 shares and shared dispositive power over 4,562,112 shares, with an aggregate beneficial ownership figure of 4,681,855 shares at 7.1% of the class.
  • Triggering event date: The date of event requiring this filing was September 30, 2026, according to the document.
  • Amendment number: This filing is Amendment No. 1 to a previously filed statement.

Wellington's Position in Stoke Therapeutics as of September 30, 2026

According to the filing, Stoke Therapeutics, Inc. (NASDAQ:STOK) is a biotechnology company headquartered at 45 Wiggins Avenue, Bedford, MA. The amended statement was filed by four Wellington entities acting as a parent holding company structure, with Wellington Management Group LLP serving as the ultimate parent. The securities reported are shares of Stoke Therapeutics common stock, identified by CUSIP number 86150R107.

The filing discloses that the shares covered by the statement "are owned of record by clients of one or more investment advisers identified in Item 7 directly or indirectly owned by Wellington Management Group LLP." Those clients, the filing states, "have the right to receive, or the power to direct the receipt of, dividends from, or the proceeds from the sale of, such securities." No single client is identified as holding more than five percent of the class. The combined 4,681,855 shares represent 7.26% of the outstanding class as stated in Item 4(b) of the filing.

Wellington Investment Advisors Holdings LLP controls, directly or indirectly through Wellington Management Global Holdings, Ltd., a group of investment advisers including Wellington Management Company LLP, Wellington Management Canada LLC, Wellington Management Singapore Pte Ltd, Wellington Management Hong Kong Ltd, Wellington Management International Ltd, Wellington Management Japan Pte Ltd, and Wellington Management Australia Pty Ltd. The filing certifies that the securities "were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer."

What Was Disclosed

Four affiliated Wellington entities filed an amended beneficial ownership statement covering 4,681,855 shares of Stoke Therapeutics common stock, equal to 7.3% of the class, with zero sole voting or dispositive power and all voting and dispositive authority held on a shared basis as of September 30, 2026.